Treating weight loss in stomach cancer with hormone therapy
Part of Cancer, Digestive system clinical trials.
This study tests whether adding the drug megestrol acetate oral suspension to standard chemotherapy and immunotherapy can help people with stomach or gastroesophageal junction cancer who are experiencing weight loss (cachexia). The goal is to improve appetite and weight while receiving neoadjuvant treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with stage III stomach or gastroesophageal junction cancer that can be removed with surgery.
- You have experienced weight loss (e.g., more than 5% in the last 6 months) or have a low body mass index (BMI) with recent weight loss.
- You have not had any previous treatment for this cancer.
- You are healthy enough to undergo surgery and are willing to receive chemotherapy and immunotherapy as part of your treatment.
- You are not pregnant, not breastfeeding, and agree to use contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This clinical trial tests whether adding an immunotherapy drug called tislelizumab to chemotherapy before surgery is better than chemotherapy alone for people with a certain type of stomach cancer. The goal is to see if the combination helps shrink the tumor and improves the chance of successful surgery.
This trial tests giving a combination of immunotherapy, a growth factor to boost white blood cells, and chemotherapy before surgery for stomach cancer. The goal is to shrink the tumor and improve surgical outcomes.
This trial tests a combination of immune therapy and chemotherapy given before surgery for stomach or esophagus-stomach cancer. The goal is to shrink the tumor to make surgery more effective and possibly improve outcomes.
This study tests combining an immunotherapy drug (PD-1 inhibitor) and a medication to boost your immune system (thymalfasin) with standard chemotherapy and radiation before surgery for stage III cancer where the stomach meets the esophagus. The goal is to see if this approach can shrink the tumor and improve outcomes.
Hear when a new Stage III Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.